NLRP3 Inflammasome Activation in Intestinal Inflammation

The NLRP3 inflammasome is a multiprotein complex central to innate immunity in the gastrointestinal tract. Upon sensing microbial ligands, metabolic disturbance or endogenous danger signals, NLRP3 assembles with the adaptor protein ASC and pro-caspase-1, leading to caspase-1 activation. Active caspase-1 cleaves pro-interleukin-1β and pro-interleukin-18 into their mature forms and initiates pyroptosis, a lytic form of cell death that expels infected or damaged cells. In the healthy gut, controlled NLRP3 activation supports barrier integrity, microbial homeostasis and mucosal repair. However, dysregulated or hyperactive NLRP3 signalling can drive excessive cytokine release and uncontrolled pyroptosis, contributing to chronic conditions such as ulcerative colitis and Crohn’s disease. Recent advances have elucidated mechanisms of canonical and non-canonical NLRP3 activation, highlighted cross-talk with the microbiota and identified both protective and detrimental roles depending on cellular context. Understanding these pathways has unlocked new therapeutic strategies, from small-molecule inhibitors to lipid modulators and natural compounds, with the ultimate aim of restoring intestinal homeostasis without compromising host defence.

Research from Nature Portfolio

Studies using selective NLRP3 inhibitors in murine colitis models have shown remarkable amelioration of intestinal inflammation. One investigation demonstrated that a potent small-molecule antagonist reduces colonic thickening, histopathological damage and pro-inflammatory cytokine secretion in a spontaneous ulcerative colitis model. Separate work in mice carrying a hyperactive NLRP3 variant revealed that controlled escalation of interleukin-1β drives remodelling of the gut microbiota and enhances regulatory T cell induction, thereby preserving epithelial barrier function and resisting chemically induced colitis. Another experimental programme confirmed that inflammasome-derived cytokines interleukin-1β and interleukin-18 can have a protective effect in an oxazolone-induced colitis setting, with exogenous supplement of these cytokines reversing mucosal damage and restoring mucin production.

NLRP3 Inflammasome Activation in Intestinal Inflammation publication trend

The graph below shows the total number of articles in nlrp3 inflammasome activation in intestinal inflammation across all publications each year (not limited to Nature Index journals).

Technical terms

NLRP3 inflammasome: A cytosolic protein complex that senses cellular stress and assembles to activate caspase-1 and initiate inflammatory cytokine maturation.

Caspase-1: A protease activated within the inflammasome that cleaves pro-interleukin-1β and pro-interleukin-18 into active cytokines and triggers pyroptosis.

Interleukin-1β (IL-1β): A potent pro-inflammatory cytokine produced upon caspase-1 cleavage, driving fever, immune cell recruitment and epithelial responses.

Pyroptosis: A form of programmed cell death characterised by pore formation in the plasma membrane, cell swelling and release of inflammatory mediators.

References

1. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cellular & Molecular Biology Letters (2023).
2. Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. Frontiers in Immunology (2017).
3. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Scientific Reports (2018).
4. Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis. Nature Communications (2017).
5. NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis. Scientific Reports (2016).
6. PI(4,5)P2 alleviates colitis by inhibiting intestinal epithelial cell pyroptosis through NNMT-mediated RBP4 m6A modification. Cell Death & Disease (2024).
7. Homotherapy for heteropathy: therapeutic effect of Butein in NLRP3-driven diseases. Cell Communication and Signaling (2024).
8. A randomized, double‐blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clinical and Translational Medicine (2023).